Pharma News, 2024

Health care providers have a responsibility to ensure that we are not replacing one public health crisis with another

ThinkCyte today announced the successful completion of its Series C funding round. Including the equity financing secured last November, the company raised an additional $15 million in the extension r...

Emergent BioSolutions has received approval from the US Food and Drug Administration (FDA) for its supplemental biologics licence application for ACAM2000, (Smallpox and Mpox (Vaccinia...

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) to authorise the use of nipocalimab fo...

Bolstered by the latest preclinical data, Psilera is poised to advance their lead asset, PSIL-006, towards first-in-human studies for Frontotemporal Dementia (FTD).

The US Food and Drug Administration (FDA) is set to decide on whether to approve Soleno Therapeutics’ lead therapy, diazoxide choline (DCCR), for treating hyperphagia associated with...

The European Commission (EC) has authorised Astellas Pharma‘s PADCEV (enfortumab vedotin) in combination with KEYTRUDA (pembrolizumab) for first-line treatment of advanced ur...

Flagship Pioneering today demonstrated further acceleration in its strategic partnership with Pfizer Inc, announcing two research programs with Flagship-founded Quotient Therapeutics. Under the collab...

Vaxart, Inc. today announced the publication of preclinical data demonstrating the potential of its mucosal vaccine technology platform in enabling therapeutic vaccination against HPV-related cervical...

People with multiple sclerosis (MS) are far less likely than those without the condition to have the molecular hallmarks of Alzheimer's disease, according to new research from Washington U...

A FDA advisory committee (AdComm) is set to evaluate Lexicon’s Zynquista as an adjunct therapy for type 1 diabetes and chronic kidney disease.

Arthrosi Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to its investigational drug AR882, aimed at treating gout patients with cl...